Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ESSA Pharma
Vancouver, British Columbia, Canadaessapharma.com ↗
- Ownership
- Public · EPIX
- Employees
- ~50
- Development stage
- Other
01
Overview
ESSA’s lead asset, masofaniten (formerly EPI‑7386), was an oral small molecule targeting the androgen receptor’s N-terminal domain. The most advanced trial—a Phase II study in combination with enzalutamide for mCRPC—was halted after interim analysis showed no efficacy benefit over standard therapy. All other masofaniten studies were also discontinued. The company may have preclinical assets but has ceased active R&D and entered strategic review.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Bayer and Janssen supported respective combination trials with their antiandrogens.Astellas partnered for one combination trial.
Beyond the preview
Go deeper on ESSA Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ESSA Pharma.